MedTrace Logo

A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants

NCT04487405 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 721

Last updated 2023-12-26

No results posted yet for this study

Summary

The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.

Conditions

  • Adnexal Mass

Interventions

DEVICE

OVAnex

OVAnex is a multivarite index assay assessing ovarian cancer risk

Sponsors & Collaborators

  • Aspira Women's Health

    lead INDUSTRY

Principal Investigators

  • Todd Pappas, PhD · Aspira Women's Health

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-25
Primary Completion
2023-12-15
Completion
2023-12-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04487405 on ClinicalTrials.gov